OCUL · Ocular Therapeutix, Inc · Webcasts, Transcripts & Audio
$5.99
+0.05 (+0.76%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.31B
Shares
220.02M
Volume · Nov 19
220.23K
Avg daily vol (3M)
3.04M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Ocular Therapeutix, Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Ocular Therapeutix, Inc (OCUL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-17
Ocular Therapeutix, Inc (OCUL) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-09
Ocular Therapeutix, Inc (OCUL) Q3 2026 Earnings Call Transcript
Confident tone
SOLAR trial design and primary endpoint change
SOL1 Phase III superiority results
Competitive landscape and differentiation
Revenue
$12.87M
▼ 11.5% YoY Diluted EPS
$-0.42
Gross margin
88.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-10-20
Ocular Therapeutix, Inc (OCUL) October 20, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-18
Ocular Therapeutix, Inc (OCUL) Q2 2026 Earnings Call
Revenue
$13.47M
▲ 0.1% YoY Diluted EPS
$-0.35
Gross margin
85.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-12
Ocular Therapeutix, Inc (OCUL) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Ocular Therapeutix, Inc (OCUL) Q1 2026 Earnings Call Transcript
Confident tone
X-Paxly SOL1 Phase 3 superiority in wet AMD
SOLAR confirmatory trial
NDA submission and regulatory pathway
Revenue
$10.79M
▲ 0.8% YoY Diluted EPS
$-0.40
Gross margin
87.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-05
Ocular Therapeutix, Inc (OCUL) Q4 2025 Earnings Call
Revenue
$13.25M*
▼ 22.4% YoY Gross margin
88.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Ocular Therapeutix, Inc (OCUL) Q3 2025 Earnings Call Transcript
Confident tone
AXPAXLI superiority label strategy
SOL-1 and SOL-R wet AMD registrational trials
HELIOS diabetic retinopathy program
Revenue
$14.54M
▼ 5.7% YoY Diluted EPS
$-0.38
Gross margin
87.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Ocular Therapeutix, Inc (OCUL) Q2 2025 Earnings Call Transcript
Confident tone
AXPAXLI registrational program / SOL trials
Trial quality, retention and rescue conduct
SOL-1 top-line data readout
Revenue
$13.46M
▼ 18.1% YoY Diluted EPS
$-0.39
Gross margin
85.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Ocular Therapeutix, Inc (OCUL) Q4 2024 Earnings Call Transcript
Confident tone
AXPAXLI registrational program in wet AMD
SOL-R trial optimization and sample size reduction
FDA SPA amendment and redosing strategy
Revenue
$17.08M*
▲ 15.4% YoY Gross margin
92.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Ocular Therapeutix, Inc (OCUL) Q3 2024 Earnings Call Transcript
Confident tone
AXPAXLI Wet AMD SOL-1 and SOL-R Trials
Diabetic Retinopathy / DME Opportunity
Regulatory Pathway / FDA
Revenue
$15.43M
▲ 2.3% YoY Diluted EPS
$-0.22
Gross margin
89.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Ocular Therapeutix, Inc (OCUL) Q2 2024 Earnings Call Transcript
Confident tone
SOL-1 registration study enrollment
SOL-R repeat-dosing registration study
FDA alignment on study designs
Revenue
$16.44M
▲ 8.3% YoY Diluted EPS
$-0.26
Gross margin
90.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Ocular Therapeutix, Inc (OCUL) Q1 2024 Earnings Call
Revenue
$14.77M
▲ 10.5% YoY Diluted EPS
$-0.49
Gross margin
91.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q3
2023-11-07
Ocular Therapeutix, Inc (OCUL) Q3 2023 Earnings Call Transcript
Revenue
$15.08M
▲ 26% YoY Diluted EPS
$-0.25
Gross margin
90.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Ocular Therapeutix, Inc (OCUL) Q2 2023 Earnings Call Transcript
Revenue
$15.19M
▲ 23.8% YoY Diluted EPS
$-0.26
Gross margin
91.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Ocular Therapeutix, Inc (OCUL) Q1 2023 Earnings Call Transcript
Revenue
$13.37M
▲ 1.4% YoY Diluted EPS
$-0.39
Gross margin
90.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-06
Ocular Therapeutix, Inc (OCUL) Q4 2022 Earnings Call Transcript
Revenue
$14.08M*
▲ 14.4% YoY Gross margin
92.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Ocular Therapeutix, Inc (OCUL) Q3 2022 Earnings Call Transcript
Revenue
$11.96M
▼ 1.5% YoY Diluted EPS
$-0.31
Gross margin
91.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Ocular Therapeutix, Inc (OCUL) Q2 2022 Earnings Call Transcript
Revenue
$12.27M
▲ 4.7% YoY Diluted EPS
$-0.25
Gross margin
90.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Ocular Therapeutix, Inc (OCUL) Q1 2022 Earnings Call Transcript
Revenue
$13.19M
▲ 79.6% YoY Diluted EPS
$-0.22
Gross margin
90.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Ocular Therapeutix, Inc (OCUL) Q4 2021 Earnings Call Transcript
Revenue
$12.31M*
▲ 67.5% YoY Gross margin
91.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Ocular Therapeutix, Inc (OCUL) Q3 2021 Earnings Call Transcript
Revenue
$12.15M
▲ 106.8% YoY Diluted EPS
$-0.23
Gross margin
89.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-22
Ocular Therapeutix, Inc (OCUL) Q2 2021 Earnings Call Transcript
Revenue
$11.72M
▲ 646.8% YoY Diluted EPS
$-0.25
Gross margin
90.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Ocular Therapeutix, Inc (OCUL) Q1 2021 Earnings Call Transcript
Revenue
$7.34M
▲ 181.4% YoY Diluted EPS
$-0.24
Gross margin
87.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Ocular Therapeutix, Inc (OCUL) Q4 2020 Earnings Call Transcript
Revenue
$7.35M*
▲ 225.8% YoY Gross margin
90.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Ocular Therapeutix, Inc (OCUL) Q3 2020 Earnings Call Transcript
Revenue
$5.88M
▲ 608.8% YoY Diluted EPS
$-0.21
Gross margin
92.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-17
Ocular Therapeutix, Inc (OCUL) Q2 2020 Earnings Call Transcript
Revenue
$1.57M
▲ 141.4% YoY Diluted EPS
$-0.64
Gross margin
91.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-08
Ocular Therapeutix, Inc (OCUL) Q1 2020 Earnings Call Transcript
Revenue
$2.61M
▲ 430.3% YoY Diluted EPS
$-0.41
Gross margin
68.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–28 of 28 webcasts
Key facts
CIK
1393434
CUSIP
67576A100
13F (30d)
269 filings
250 filers
Visit website
Investor relations